– Sixteen abstracts summarize evaluations of company’s novel echinocandin CD101 and Cloudbreak™ immunotherapy platform –
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that results of nonclinical studies of two formulations of CD101, a novel echinocandin, will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015. The company will also present one poster summarizing results from studies of its Cloudbreak™ targeted immunotherapy platform. In total, three oral presentations and 14 poster presentations regarding CD101 IV, CD101 Topical and Cloudbreak™ have been accepted for presentation.
“There remains significant unmet need for novel drugs to treat life-threatening, invasive fungal infections,” said John Perfect, M.D., professor of medicine and director of the Mycology Research Unit at Duke University Medical Center and a nationally recognized expert in infectious disease research. “It is very encouraging to see the holistic approach that Cidara Therapeutics is taking to identify multiple, novel therapies for these infections, which contribute to significant morbidity and mortality, as well as significant healthcare costs.”
The ICAAC/ICC presentations are as follows:
Friday, September 18: Oral Summary of Posters (2:30 p.m. – 2:45 p.m., Ballroom 20D Upper Level)
- Summary of Cidara Therapeutics Posters on CD101: a Novel Long-Acting IV and Topical Echinocandin; D. Thye
Friday, September 18: Slide Session 044: Pharmacokinetics/Pharmacodynamics: Reflections on a Pioneer and Emerging Approaches to Combat Antimicrobial Resistance (6:15 p.m. – 6:30 p.m., Meeting Room 31C Upper Level)
- Pharmacokinetics-Pharmacodynamics (PK-PD) of a Novel Echinocandin, CD101, in a Neutropenic Murine Disseminated Candidiasis Model; C. M. Rubino, V. Ong, D. Thye, P. G. Ambrose
Sunday, September 20: Slide Session 197: Experimental Mycology (4:15 p.m. – 4:30 p.m., Meeting Room 8 Upper Level)
- Intravenous Efficacy of a Novel Echinocandin, CD101, in Neutropenic Mouse Models of Disseminated Candidiasis and Aspergillosis; L. Miesel, H-H. Huang, W-T. You, V. Ong, K. Bartizal
Friday, September 18th
Poster Presentations 005: Pharmacokinetics/Pharmacodynamics of Antifungal Agents (12:00 p.m. – 2:00 p.m., Exhibit Hall F)
- A-015: Preclinical Evaluation Shows CD101, a Novel Echinocandin, is Highly Stable with No Hepatotoxicity in Rats; V. Ong, G. Hough, M. Schlosser, K. Bartizal, J. Balkovec, K. James, R. Krishnan
Saturday, September 19th
Poster Presentations 096 – New Anti-Fungal Agents (11:00 a.m. – 1:00 p.m., Exhibit Hall F)
- F-747: Evaluation of CD101 Glucan Synthase Inhibition, MIC Values and Mutant Prevention Concentrations Against Echinocandin-Susceptible and -Resistant Candida spp.; W. Perez, C. Jimenez-Ortigosa, D. Perlin
- F-748: Efficacy of CD101 to Treat Echinocandin-resistant Candida albicans in a Murine Model of Invasive Candidiasis; Y. Zhao, I. Kolesnikova, E. Dolgov, D. Perlin
- F-750: Structure-activity Relationship of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble, Once-weekly Novel Echinocandin; K. James, C. Laudeman, N. Malkar, R. Krishnan, K. Polowy
- F-752: Evaluation of CD101 with Echinocandin and Azole Comparators Against Candida spp. Isolated from Patients with Vulvovaginal Candidiasis (VVC); J. D. Sobel, D. Boikov, K. Bartizal, K. James
- F-753: Determination of CD101 Spontaneous Mutation Frequencies and Underlying Resistance Mechanisms in Candida spp.; A. Almaguer, J. B. Locke, D. E. Zuill, K. Bartizal
- F-754: Characterization of Resistance Following Serial Passage of Candida spp. in the Presence of CD101; J. B. Locke, D. E. Zuill, A. Almaguer, K. Bartizal
- F-755: Novel Echinocandin CD101 Gel Formulation is Highly Effective in Eradicating Candida albicans in a Rat Model of Vulvovaginal Candidiasis; L. Miesel, H-H. Huang, W-T. You, V. Ong, K. Bartizal
- F-761: Prolonged Efficacy Following a Single Dose of a Novel Echinocandin, CD101, in a Neutropenic Mouse Model of Disseminated Candidiasis; V. Ong, K. Bartizal, L. Miesel, H-H. Huang, J-C. Chien
- F-762: Bifunctional Small Molecule Immunotherapy. C-001 and C-016 Attract Neutrophils (PMNs) to Inhibit Aspergillus fumigatus (Af) Growth in Microfluidic Chambers; D. Irimia, C. Jones, K. M. Forrest, J. K. Judice, J. B. Locke, A. Almaguer, J. Balkovec.
Poster Presentations 105 – New Antifungal Agents (11:00 a.m. – 1:00 p.m., Exhibit Hall F)
- M-849: Activity of a Long-acting Echinocandin (CD101) and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates; M. Castanheira, S. A. Messer, P. R. Rhomberg, R. R. Dietrich, M. A. Pfalle
- M-850: Evaluation of the In Vitro Activity of CD101, a Novel Echinocandin, and Comparators Against Recent Clinical Isolates of Candida species; C. M. Pillar, D. Hall, R. Bonifas, D. L. Shinabarger
- M-851: Evaluation of Disk Diffusion Susceptibility Testing for CD101, a Novel Echinocandin, Against Candida species; C. M. Pillar, A. Stoneburner, D. L. Shinabarger
- M-852: Evaluation of the Fungicidal Activity of CD101, a Novel Echinocandin, and Comparators Against Recent Clinical Isolates of Candida Species; C. M. Pillar, D. Hall, D. L. Shinabarger
Copies of these posters will be available on the Cidara website following the ICAAC/ICC meeting: http://www.Cidara.com/
About Cidara Therapeutics
Cidara is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara’s initial product portfolio comprises two formulations of the company’s novel echinocandin, CD101, for the treatment of serious fungal infections. CD101 IV is a long-acting therapy for the treatment and prevention of systemic fungal infections. CD101 topical is for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California. For more information please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness and long-acting nature of CD101 IV and the intended design of current and future Cloudbreak compounds. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s documents most recently filed with the United States Securities and Exchange Commission (SEC), including its Registration Statement on Form S-1 declared effective by the SEC on April 14, 2015, under the heading “Risk Factors.” All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Source: Cidara Therapeutics, Inc.